MA38699A1 - Formulation orale pour le traitement de maladies cardiovasculaires - Google Patents

Formulation orale pour le traitement de maladies cardiovasculaires

Info

Publication number
MA38699A1
MA38699A1 MA38699A MA38699A MA38699A1 MA 38699 A1 MA38699 A1 MA 38699A1 MA 38699 A MA38699 A MA 38699A MA 38699 A MA38699 A MA 38699A MA 38699 A1 MA38699 A1 MA 38699A1
Authority
MA
Morocco
Prior art keywords
treatment
cardiovascular diseases
oral formulation
statin
acetylsalicylic acid
Prior art date
Application number
MA38699A
Other languages
English (en)
Other versions
MA38699B1 (fr
Inventor
Sanz Pablo Martin
Hurtado Javier Urbano
Original Assignee
Ferrer Int
Fundación Centro Nac De Investig Cardiovasculares Carlos Iii
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48569993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA38699(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferrer Int, Fundación Centro Nac De Investig Cardiovasculares Carlos Iii filed Critical Ferrer Int
Publication of MA38699A1 publication Critical patent/MA38699A1/fr
Publication of MA38699B1 publication Critical patent/MA38699B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition pharmaceutique qui comprend un inhibiteur de hmg-coa réductase, en particulier une statine et l'acide acétylsalicylique d'une manière à rendre minimale l'interaction de l'acide acétylsalicylique avec la statine, pour l'utilisation dans la prévention ou le traitement de maladies cardiovasculaires.
MA38699A 2013-06-06 2014-06-05 Formulation orale pour le traitement de maladies cardiovasculaires MA38699B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13170909.9A EP2810644A1 (fr) 2013-06-06 2013-06-06 Formulation orale pour le traitement de maladies cardiovasculaires
PCT/EP2014/061735 WO2014195421A1 (fr) 2013-06-06 2014-06-05 Formulation orale pour le traitement de maladies cardiovasculaires

Publications (2)

Publication Number Publication Date
MA38699A1 true MA38699A1 (fr) 2017-01-31
MA38699B1 MA38699B1 (fr) 2017-09-29

Family

ID=48569993

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38699A MA38699B1 (fr) 2013-06-06 2014-06-05 Formulation orale pour le traitement de maladies cardiovasculaires

Country Status (42)

Country Link
US (1) US10617699B2 (fr)
EP (3) EP2810644A1 (fr)
JP (1) JP6151854B2 (fr)
KR (1) KR101839665B1 (fr)
CN (2) CN104224804A (fr)
AP (1) AP2015008882A0 (fr)
AR (1) AR096350A1 (fr)
AU (1) AU2014276883B2 (fr)
BR (1) BR112015030350B1 (fr)
CA (1) CA2912350C (fr)
CL (1) CL2015003561A1 (fr)
CR (1) CR20150635A (fr)
CU (1) CU24326B1 (fr)
CY (1) CY1118766T1 (fr)
DK (1) DK2986281T3 (fr)
DO (1) DOP2015000296A (fr)
EA (1) EA028969B1 (fr)
EC (1) ECSP15050273A (fr)
ES (1) ES2620078T3 (fr)
GE (1) GEP201706743B (fr)
HK (1) HK1204562A1 (fr)
HU (1) HUE033458T2 (fr)
IL (1) IL242569B (fr)
MA (1) MA38699B1 (fr)
MD (1) MD4475C1 (fr)
MX (1) MX347801B (fr)
MY (1) MY181272A (fr)
NI (1) NI201500171A (fr)
NZ (1) NZ714707A (fr)
PE (1) PE20160051A1 (fr)
PH (1) PH12015502706B1 (fr)
PL (1) PL2986281T3 (fr)
PT (1) PT2986281T (fr)
RS (1) RS55786B1 (fr)
SA (1) SA515370243B1 (fr)
SG (1) SG11201509353QA (fr)
SI (1) SI2986281T1 (fr)
TN (1) TN2015000501A1 (fr)
TW (1) TWI630928B (fr)
UA (1) UA113806C2 (fr)
WO (1) WO2014195421A1 (fr)
ZA (1) ZA201508452B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI4197530T1 (sl) * 2015-04-16 2026-03-31 Novartis Ag Tableta ribocikliba
CN111135149B (zh) * 2018-11-04 2021-05-11 张家港市中医医院 一种瑞舒伐他汀钙片及其制备方法
CN110693929A (zh) * 2019-09-09 2020-01-17 安徽中医药大学 复方药物组份在治疗脑梗死恢复期中的应用
PL4299063T3 (pl) * 2022-06-30 2024-06-10 Ferrer Internacional, S.A. Kapsułki doustne zawierające tabletki atorwastatyny wykazujące odpowiedni profil rozpuszczania i biodostępność
MX2024011227A (es) 2024-09-12 2026-04-01 Laboratorios Silanes S A De C V Composicion farmaceutica que comprende rosuvastatina y acido acetilsalicilico, proceso de preparacion y usos de la misma

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
HU204253B (en) 1982-11-22 1991-12-30 Sandoz Ag Process for producing mevalonolactone analogues and derivatives and pharmaceutical compositions containing them
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
JP2000508659A (ja) * 1996-04-17 2000-07-11 メルク エンド カンパニー インコーポレーテッド 心血管疾患関連の危険性を低減する組み合わせ療法
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6448323B1 (en) 1999-07-09 2002-09-10 Bpsi Holdings, Inc. Film coatings and film coating compositions based on polyvinyl alcohol
EP1272165B1 (fr) 2000-02-10 2010-12-01 BPSI Holdings, Inc. Compositions acryliques d'enrobage enterique
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
US20040115265A1 (en) 2002-12-11 2004-06-17 Loutfy Benkerrour Multilayered tablet containing pravastatin and aspirin and method
WO2004080488A2 (fr) 2003-03-10 2004-09-23 Bayer Healthcare Ag Preparations combinees d'acide acetylsalycilique pour la prevention primaire de maladies cardiovasculaires
EP1648422A4 (fr) * 2003-07-28 2007-09-19 Reddys Lab Inc Dr Traitement et prevention d'accidents cardiovasculaires
WO2005019286A1 (fr) 2003-08-20 2005-03-03 Shionogi & Co., Ltd. Nouvelle composition pour revetements
CA2600973C (fr) 2003-11-26 2012-08-07 Novartis Ag Acide .delta.-amino-.gamma.-hydroxy-.omega.-arylalcanoique
US20090098201A1 (en) * 2004-06-28 2009-04-16 Bio Intellectual Property Services (Bio Ips) Llc Composition and Method for Treatment and Prevention of Atherosclerosis
BRPI0609158A2 (pt) 2005-03-11 2010-02-23 Speedel Experimenta Ag alcanamidas substituìdas heterocìclicas úteis como inibidores de renina
US20070009591A1 (en) 2005-07-07 2007-01-11 Trivedi Jay S ACE inhibitor formulation
US20070116756A1 (en) 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
US7427414B2 (en) 2006-01-18 2008-09-23 Astron Research Limited Modified release oral dosage form using co-polymer of polyvinyl acetate
CN101176725A (zh) * 2006-07-14 2008-05-14 兰贝克赛实验室有限公司 辛伐他汀和阿司匹林的稳定剂型
CA2677623C (fr) * 2007-02-09 2015-04-07 Alphapharm Pty Ltd Forme pharmaceutique contenant deux ou davantage de principes actifs pharmaceutiques sous des formes physiques differentes
KR100955669B1 (ko) 2007-08-13 2010-05-06 한올바이오파마주식회사 ＨＭＧ­ＣｏＡ 환원효소 저해제와 아스피린을 포함하는 복합제제 및 그의 제조방법
US20090076062A1 (en) 2007-09-13 2009-03-19 Juergen Klaus Maibaum Organic Compounds
UA99758C2 (ru) * 2008-03-28 2012-09-25 Феррер Интернасиональ С.А. Капсула для профилактики сердечно-сосудистых заболеваний
EP2395838B1 (fr) * 2009-02-11 2018-07-25 Cadila Pharmaceuticals Ltd. Composition pharmaceutique stable pour l'athérosclérose
AU2010242938A1 (en) * 2009-04-30 2011-11-17 Dr. Reddy's Laboratories Ltd. Fixed dose drug combination formulations
US20130005730A1 (en) 2009-11-09 2013-01-03 Piaoyang Sun Novel 1,3-oxazolidine compounds and their use as renin inhibitors
KR101193493B1 (ko) * 2010-02-02 2012-10-22 한미사이언스 주식회사 소수성 첨가제가 함유된 분리막으로 코팅된 아스피린 및 ＨＭＧ?ＣｏＡ 환원효소 억제제를 포함하는 복합제제
CN102049049A (zh) * 2010-11-27 2011-05-11 王定豪 包含阿司匹林盐和他汀类药物的药物组合物

Also Published As

Publication number Publication date
EP2986281B1 (fr) 2016-12-21
AR096350A1 (es) 2015-12-23
TN2015000501A1 (en) 2017-04-06
EP3175849A1 (fr) 2017-06-07
TW201536357A (zh) 2015-10-01
HK1204562A1 (en) 2015-11-27
PH12015502706A1 (en) 2016-03-14
ZA201508452B (en) 2017-02-22
BR112015030350B1 (pt) 2022-11-29
CN113143888A (zh) 2021-07-23
CU20150173A7 (es) 2016-06-29
MX2015015753A (es) 2016-08-03
CU24326B1 (es) 2018-03-13
CA2912350A1 (fr) 2014-12-11
BR112015030350A2 (pt) 2017-07-25
MX347801B (es) 2017-05-15
MA38699B1 (fr) 2017-09-29
UA113806C2 (xx) 2017-03-10
EP2810644A1 (fr) 2014-12-10
PH12015502706B1 (en) 2016-03-14
CN104224804A (zh) 2014-12-24
PE20160051A1 (es) 2016-01-25
NZ714707A (en) 2019-04-26
WO2014195421A1 (fr) 2014-12-11
MD4475B1 (ro) 2017-04-30
SG11201509353QA (en) 2015-12-30
SI2986281T1 (sl) 2017-07-31
US20160106763A1 (en) 2016-04-21
CA2912350C (fr) 2017-04-04
KR20160014622A (ko) 2016-02-11
CY1118766T1 (el) 2017-07-12
EA028969B1 (ru) 2018-01-31
JP6151854B2 (ja) 2017-06-21
NI201500171A (es) 2019-05-07
AP2015008882A0 (en) 2015-11-30
RS55786B1 (sr) 2017-07-31
GEP201706743B (en) 2017-09-25
CR20150635A (es) 2016-06-10
AU2014276883A1 (en) 2015-11-26
PT2986281T (pt) 2017-03-29
EA201600012A1 (ru) 2016-07-29
AU2014276883B2 (en) 2017-04-20
MD20160001A2 (ro) 2016-05-31
MY181272A (en) 2020-12-21
PL2986281T3 (pl) 2017-06-30
SA515370243B1 (ar) 2016-09-19
TWI630928B (zh) 2018-08-01
CL2015003561A1 (es) 2016-06-10
KR101839665B1 (ko) 2018-03-16
DOP2015000296A (es) 2016-12-30
ES2620078T3 (es) 2017-06-27
DK2986281T3 (en) 2017-04-03
EP2986281A1 (fr) 2016-02-24
ECSP15050273A (es) 2017-07-31
HUE033458T2 (en) 2017-12-28
US10617699B2 (en) 2020-04-14
IL242569B (en) 2018-12-31
JP2016520135A (ja) 2016-07-11
MD4475C1 (ro) 2017-11-30

Similar Documents

Publication Publication Date Title
MA44312A (fr) Anticorps et leurs méthodes d'utilisation
TN2019000099A1 (fr) Anticorps anti-lag-3 et compositions
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA40576A (fr) Anticorps et immunoconjugués anti-her2
MA45450B1 (fr) Formulations d'anticorps anti-cd19
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
BR112013008140A8 (pt) "compostos imidazotriazinona".
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
MA38699B1 (fr) Formulation orale pour le traitement de maladies cardiovasculaires
EP2572721A4 (fr) Composition pharmaceutique comprenant un inhibiteur de hif-2 comme ingrédient actif pour la prévention ou le traitement de l'arthrite
MA41072A1 (fr) Nouvelles protéines spécifiques de la pyoverdine et de la pyochéline
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA50406B1 (fr) Inhibiteurs pyrazole de magl
GEAP202215599A (en) Boron containing pde4 inhibitors
FR3058059B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol et le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
WO2018094300A8 (fr) Protéines de liaison à un antigène anti-gitr et leurs procédés d'utilisation
MA34709B1 (fr) Compositions pharmaceutiques
MA40844A (fr) Compositions pharmaceutiques à action prolongée pour l'hépatite c
FR3061021B1 (fr) Antagoniste specifique de tlr4 dans le traitement du myelome multiple
FR3040303B1 (fr) Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca
MA30374B1 (fr) Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine
MA45609B1 (fr) Compositions d'acide cromoglicique pour le traitement de la dermatite
FR3058060B1 (fr) Composition pharmaceutique comprenant le beta-elemene, le lupeol, le cinnamaldehyde et/ou le 2-hydroxycinnamaldehyde et/ou le 2'-benzoyloxycinnalmaldehyde et/ou le beta-sitosterol et/ou la curcumine.
MA34232B1 (fr) Association d'inhibiteurs de la xanthine oxydase et de statines et son utilisation
ES2524645B1 (es) Formulación oral para el tratamiento de enfermedades cardiovasculares